Trial Profile
A Phase 2 clinical trial investigating the ability of CX717 to improve breathing in patients with spinal cord injury
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 29 Apr 2021
Price :
$35
*
At a glance
- Drugs CX 717 (Primary)
- Indications Respiratory insufficiency; Spinal cord injuries
- Focus Therapeutic Use
- 22 Apr 2021 According to a RespireRx Pharmaceuticals media release, the Company is working with researchers at highly regarded clinical sites to finalize a Phase 2 clinical trial protocol. The company believes that a clinical study could be initiated within several months of raising sufficient financing (of which no assurance can be provided).
- 22 Jun 2017 New trial record
- 14 Jun 2017 According to a RespireRx Pharmaceuticals media release, the company is planning to file an INDand initiate this trial during 2017.